If that is the case, maybe it has something to do with a higher likelihood of adverse experiences in the rave group, maybe driven in part by their higher levels of baseline anxiety interacting with the less controlled setting? And/or drug purity? And/or polydrug use?
20.04.2025 13:56 β π 3 π 0 π¬ 0 π 0
But it's a great study that inches open the door on the question of what is *actually* needed to benefit from psychedelics! I'm also intrigued by what looks like (?) higher variability in rave group outcomes. Despite overall equivalence with retreat group, ravers seem to have more spread/outliers
20.04.2025 13:56 β π 3 π 0 π¬ 2 π 0
I came to make a similar point. Returning psychedelic users who hold therapeutic intent will rarely feel they've come away empty-handed. And it seems that ITPU history was significantly higher in the rave group than the retreat group, so this factor may have driven improvements differentially there.
20.04.2025 13:56 β π 2 π 0 π¬ 1 π 0
Great interview!
18.04.2025 19:43 β π 1 π 0 π¬ 1 π 0
YouTube video by Mahindra Humanities Center
Psychedelic Projections: What do Psychedelics Really Offer? | Franklin King
A great (and not too long) discussion from Franklin King on psychedelics' putative potential to radically shift models of care & healing
16.04.2025 21:35 β π 4 π 0 π¬ 0 π 0
An Open Letter Reply to Dr. Stan Grof - OPEN Foundation
In this open letter, leading voices in the psychedelic field including Alex Belser, Andrea Ens, Bill Brennan, Dee Dee Goldpaugh, and Jeff Guss respond to Stanislav Grofβs recent statement addressing t...
Conversion therapy is a psuedo-therapeutic evil that we can't let take root in psychedelic treatments any more than it already has. We offer this letter in the spirit of drawing a clear line in the sand against such practices.
**If you agree, please sign the consensus statement at the bottom!**
28.03.2025 18:46 β π 2 π 0 π¬ 0 π 0
I've got a friend who's a present leader in healthcare labor who used to be a journalist writing on the subject (and thus has extensive knowledge about it). He said he'd be happy to speak, though he couldn't be attributed in an article because of job restrictions. Would that be helpful?
22.11.2024 15:24 β π 1 π 0 π¬ 1 π 0
Manuscript by Charles Savage: "A Review of LSD and Alcoholism" by Ludwig, Levine, and Stark., undated | Archives and Special Collections
Now that we're all acquainted, could I ask a favor?
Does anyone have the full text of this manuscript they can send me:
archives.lib.purdue.edu/repositories...
From the bits I've read, its critique strikes me as relevant to where we're currently at
18.11.2024 15:15 β π 2 π 0 π¬ 0 π 0
Hi there ποΈ Iβm Bill, and I live in the Catskills, NY.
1) Consultant and trainer at Cybin, Gilgamesh, & others. Co-creator of EMBARK: a.co/d/gw2K0qq
2) GuideSite Consulting: guidesiteconsulting.com
3) Finishing βMy Brilliant Friend,β which has been RIVETING.
4) Catβs name is Moose.
17.11.2024 20:54 β π 6 π 0 π¬ 0 π 0
GuideSite Consulting | Supporting Skillful Psychedelic Care
Empowering your psychedelic research site or treatment clinic with holistic support, consultation, and training options.
2) Iβve recently co-founded GuideSite Consulting, which helps sites & clinics prepare to administer psychedelic treatments in ways that support efficacy & participant well-being. Our trainings hew close to what participants have told us about their experiences: guidesiteconsulting.com
17.11.2024 20:35 β π 0 π 0 π¬ 0 π 0
At long last, the EMBARK book is available to purchase! Alex & I hope it is of service to the field as it finds its way forward.
a.co/d/isu50BX
14.05.2024 23:06 β π 7 π 0 π¬ 0 π 0
Fantastic article! Thanks for writing it
09.03.2024 21:38 β π 2 π 0 π¬ 1 π 0
Did Compass minimize adverse experiences in its psilocybin trial?
One of the trial participants thinks so
A must-read interview w/ a patient who experienced persisting adverse effects post-psilocybin. "When the trial ended, it was like going from great support to no support. If you introduce psychedelic therapy, and there's no support set up once the treatment finishes, you shouldn't go ahead with it."
23.02.2024 18:56 β π 3 π 0 π¬ 0 π 0
I quit cold turkey a few years ago, and it was rough
20.02.2024 15:49 β π 1 π 0 π¬ 0 π 0
Psychedelic therapy & the Metaphysical Menu
Would you like a side-order of Spinoza with that?
It was a pleasure to exchange thoughts with the always-great Ed Prideaux on Peter Sjostedt-Hughes' proposal to incorporate didactics on metaphysics into psychedelic therapy. TLDR: I think it's risky to offer to suggestible patients, but potentially a great competency for therapists to get trained in
03.02.2024 21:01 β π 4 π 0 π¬ 0 π 0
25.01.2024 13:40 β π 1 π 0 π¬ 0 π 0
His next sentence after that quote: "And that's why we do science." Eat truth, fallible minds!
06.01.2024 20:52 β π 1 π 0 π¬ 0 π 0
is that we're not really respecting the fact that there's a brain involved as well as a reporting mind. And reporting minds, particularly smart ones, have very developed mechanisms for fooling themselves." (2/2)
06.01.2024 20:17 β π 2 π 0 π¬ 1 π 0
I've been sitting with a Goodwin quote from his debate with @trpwolff.bsky.social that captures this well: "The risk that we run, if we interpret the very spectacular things that people tell us about their experience as the causal mechanisms for their recovery (1/n)
06.01.2024 20:16 β π 2 π 0 π¬ 1 π 0
Agreed. And it's disappointing because if there were ever an opportunity to reconsider this dualism, it's PAT. I appreciated the Deckel et al piece's critique of Goodwin's complaint abt PAT's "odd dualism," which stems from this misunderstanding the "reciprocal & iterative" drug-therapy relationship
06.01.2024 20:14 β π 1 π 0 π¬ 1 π 0
Thanks for the very cogent response, Eduardo! Particularly for so clearly naming the market incentive to downplay the therapy and overlook the associated risks
02.01.2024 20:16 β π 2 π 0 π¬ 1 π 0
Belser and Brennan on the EMBARK model
And what they think existing models of psychedelic-assisted therapy leave out
It was great to speak to Jules Evans (one of my favorite voices in the space) about EMBARK, the model of psychedelic treatment I developed with Alex Belser. He asked some very good questions:
www.ecstaticintegration.org/p/belser-and...
15.12.2023 15:20 β π 2 π 0 π¬ 0 π 0
Max, deep thanks to you and your colleagues for this important article!
13.12.2023 15:54 β π 1 π 0 π¬ 1 π 0
Let's! December is a bit overstuffed for me, but let's circle back around in January
04.12.2023 14:02 β π 1 π 0 π¬ 0 π 0
Just read it. I love your authorial voice! And I'm grateful for the paper's project of linking of drug effects/treatment dynamics to a real-world instance of harm likely to be replicated post-FDA approval - something that hasn't yet been done in so thorough a way in the peer-reviewed literature π
02.12.2023 16:24 β π 1 π 0 π¬ 0 π 0
I'll give it a read ASAP!
01.12.2023 14:15 β π 1 π 0 π¬ 1 π 0
βWe are All Oneβ, and Other Proverbs of Spiritual Bypassing
In the first entry of the Critical Mental Health and Orientalism series, Ayesha Manazir Siddiqi examines the apolitical tendencies of Western healing spaces, and how these tendencies can prevent moβ¦
A moving and illuminating account of how the political gets swept under the rug of transcendence in psychedelic healing spaces - and its return in the form of a thousand unspoken cracks in some attendees' sense of safety
30.11.2023 23:18 β π 3 π 0 π¬ 0 π 0
CEO @ Psychedelics Today
psychedelicstoday.com
https://linktr.ee/jomo137
Sold my soul to the psychedelic revolution or whatever.
Psychedelic Science and Policy from across the open internet
psychiatrist, harm reductionist, musician, mom, psychonaut,
cannabis-and-other-psychedelics-literate clinician, h/o medical monitor for MDMA PTSD studies, also for cannabis PTSD studies,
medical advisor to MAPS++, scientific advisor to Palo Santo VC ++
Psychedelic research consultant with 15 years clinical trial management and medical affairs experience.
Check out my services and connect directly at luminousrcs.com
sociologist of science, technology, and medicine, psychedelics / writer / activist / science communicator /// Karl Landsteiner University of Health Sciences, Division of Bioethics and Public Health Ethics, Austria
Psychiatrist/Instructor, Mass General Hospital/Harvard Medical School | antireductionist, subjective experience, psychedelics | my views
Ethnographic documentation of Healing and Transformation Culture through the Spectacle of social media.
Humanist + events prof. Cannabis & psychedelic advocate, mother, and poet.
Ξ¨/Seeker. Adjunct Prof (University of Toronto and University of Ottawa). Collabs with Psychedelics Today, Mind Europe, CIIS,
Erasmus Rotterdam School of Management, CAMH Research, Beckley Retreats, Fluence, etc β¨
Exploring the potential of psychedelics for the betterment of all. @UC Berkeley
A 501(c)(3) non-profit entity created for patent reviewers around the world, to help find relevant prior art in the field of psychedelics. π¦ Help us protect public access to psychedelic therapeutics at portasophia.org
Neuroscientist working on the neurophenomenology of psychedelics, breathwork & meditation | PhD at University of Cambridge
Unapologetic advocate for positive social change, social justice, & individual/community empowerment. Scholar-Activist | Writer | Dancer | Professor | Psychologist | Organizational Consultant | Psychedelic Advocate
Author of nine books, including The Omnivoreβs Dilemma and How to Change Your Mind. Website: Michaelpollan.com
psychedelics, mental imagery, microdosing, depression @ McMasterU
Interested in the co-evolving epistemics, therapeutics & economics of extreme experiences.
Co-lead, http://www.psychedelictherapynz.org; Dadx2
Bringing psychedelic science to the masses one monthly podcast at a time πποΈ Hosted by Dr. Alaina M. Jaster π§ Season 5 airs August 5!
Psychedelicbrainscience.com